Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 13;22(1):115.
doi: 10.1186/s12916-024-03302-5.

Investigating the nexus of metabolic syndrome, serum uric acid, and dementia risk: a prospective cohort study

Affiliations

Investigating the nexus of metabolic syndrome, serum uric acid, and dementia risk: a prospective cohort study

Tara Sr Chen et al. BMC Med. .

Abstract

Background: The global dementia prevalence is surging, necessitating research into contributing factors. We aimed to investigate the association between metabolic syndrome (MetS), its components, serum uric acid (SUA) levels, and dementia risk.

Methods: Our prospective study comprised 466,788 participants without pre-existing MetS from the UK Biobank. We confirmed dementia diagnoses based on the ICD-10 criteria (F00-03). To evaluate the dementia risk concerning MetS, its components, and SUA levels, we applied Cox proportional hazards models, while adjusting for demographic factors.

Results: Over a median follow-up of 12.7 years, we identified 6845 dementia cases. Individuals with MetS had a 25% higher risk of all-cause dementia (hazard ratio [HR] = 1.25, 95% confidence interval [CI] = 1.19-1.31). The risk increased with the number of MetS components including central obesity, dyslipidemia for high-density lipoprotein (HDL) cholesterol, hypertension, hyperglycemia, and dyslipidemia for triglycerides. Particularly for those with all five components (HR = 1.76, 95% CI = 1.51-2.04). Dyslipidemia for HDL cholesterol, hypertension, hyperglycemia, and dyslipidemia for triglycerides were independently associated with elevated dementia risk (p < 0.01). MetS was further linked to an increased risk of all-cause dementia (11%) and vascular dementia (VD, 50%) among individuals with SUA levels exceeding 400 μmol/L (all-cause dementia: HR = 1.11, 95% CI = 1.02-1.21; VD: HR = 1.50, 95% CI = 1.28-1.77).

Conclusions: Our study provides robust evidence supporting the association between MetS, its components, and dementia risk. These findings emphasize the importance of considering MetS and SUA levels in assessing dementia risk, offering valuable insights for prevention and management strategies.

Keywords: Alzheimer’s dementia; Dementia; Metabolic syndrome; Risk factors; Serum uric acid; Vascular dementia.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Participant inclusion flow diagram
Fig. 2
Fig. 2
Subgroup analyses of metabolic syndrome components and dementia risk. a Subgroup analyses stratified by age, gender, and UK Biobank assessment centers. Adjusted for various factors, including race, deprivation index, lifestyle habits, and medication history
Fig. 3
Fig. 3
Non-linear association between metabolic syndrome components and all-cause dementia risk. Restricted cubic spline models, with knots at the 10th, 50th, and 90th percentiles, were employed. Reference levels (HR fixed at 1.0) for each plot: A BMI: 27.42 kg/m2; B cholesterol: 5.69 mmol/L; C HDL: 1.45 mmol/L; D LDL: 3.56 mmol/L; E glucose: 5.12 mmol/L; F HbA1c: 36.08 mmol/L; G SBP: 139.6 mm Hg; H DBP: 82.25 mm Hg; I WC: 90.27 cm; J TG: 1.74 mmol/L Adjustments were made for age, gender, and UK Biobank assessment centers. Additional adjustments included race, index of multiple deprivation, smoking status, alcohol consumption, physical activity, portions of fruit and vegetable intake, regular medications (multivitamin use, mineral supplement, non-steroidal anti-inflammatory drugs, and aspirin), and history of dementia

References

    1. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–46. doi: 10.1016/S0140-6736(20)30367-6. - DOI - PMC - PubMed
    1. Wilson PWF, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and Type 2 Diabetes Mellitus. Circulation. 2005;112(20):3066–72. doi: 10.1161/CIRCULATIONAHA.105.539528. - DOI - PubMed
    1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640. doi: 10.1161/CIRCULATIONAHA.109.192644. - DOI - PubMed
    1. Machado-Fragua MD, Fayosse A, Yerramalla MS, van Sloten TT, Tabak AG, Kivimaki M, et al. Association of metabolic syndrome with incident dementia: role of number and age at measurement of components in a 28-year follow-up of the Whitehall II Cohort Study. Diabetes Care. 2022;45(9):2127–35. doi: 10.2337/dc22-0206. - DOI - PMC - PubMed
    1. Tang X, Zhao W, Lu M, Zhang X, Zhang P, Xin Z, et al. Relationship between central obesity and the incidence of cognitive impairment and dementia from cohort studies involving 5,060,687 participants. Neurosci Biobehav Rev. 2021;130:301–13. doi: 10.1016/j.neubiorev.2021.08.028. - DOI - PubMed

Publication types

LinkOut - more resources